MYBL2 and cancer: Our finding that hypoxic cells are particularly sensitive to B‐MYB silencing raises the interesting possibility that B‐MYB inhibitors could not only be useful for repressing the growth of oxygenated cancer cells, but may have the additional benefit to target the therapeutically challenging population of hypoxic cancer cells.